Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifapentine in tuberculosis
ChiCTR1800019294Phase 4Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center, China
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rifapentine in Tuberculosis (TB) (3 arms), sponsored by Shanghai Public Health Clinical Center, China. Primary endpoints: Plasma rifapentine concentrations during the initial 8 weeks of treatment and Incidence of rifapentine-related adverse events during the initial 8 weeks of treatment. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR1800019294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019294.